Ellex is committed to helping you better diagnose, manage and treat a wide range of visual problems and eye diseases. Whether you are involved in the treatment and diagnosis of cataract, glaucoma or retinal disease, Ellex has a solution for your practice, and for your patients.

Product Portfolio


Offering superior energy control, a sharp-edged aiming beam and the fastest firing rate at 3 shots per second, Ellex’s proprietary SLT technology allows you to visualize the TM in greater detail, and to perform procedures faster and with improved accuracy.


Canaloplasty revitalizes aqueous outflow, provides excellent IOP control, and does not require a bleb or result in bleb-related complications – providing an unprecedented level of efficacy and safety in the surgical treatment of glaucoma.


YAG laser vitreolysis offers a simple outpatient-based treatment for vitreous opacities and strands. Highly effective, it has a low complication rate and offers a high degree of patient satisfaction. Featuring perfectly coaxial illumination and ultra-low energy optical breakdown, Ultra Q Reflex™ is ideally suited to the treatment of floaters.


The tough demands of today’s new-generation intraocular lenses (IOLs) require an ever-increasing level of accuracy during YAG surgery. For this reason, Ellex YAG lasers feature state-of-the-art technology designed to achieve precise optical breakdown at the lowest energy levels possible.


Ellex solid-state photocoagulators provide safe, predictable and consistent energy delivery through a true, continuous-wave laser beam. Offering superior energy distribution from beginning to end of exposure, and across the full diameter of the treatment spot, each system delivers consistently better performance in the treatment of retinal disease.

Retinal Rejuvenation

A non-thermal laser therapy, Retinal Rejuvenation Therapy (2RT™) stimulates a natural, biological healing response in the eye to treat early Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).


Ultrasound is one of the most fundamental diagnostic tools in ophthalmology. Even in an era of high-tech OCT scanning and digital imaging, ultrasound is the only means to obtain a crucial view of the posterior segment when there is a dense cataract or vitreous hemorrhage in the eye.



The website www.slt-ellex.com provides access to a comprehensive database of information, including treatment protocols and an interactive bibliography.


Canaloplasty website

An online resource dedicated to Canaloplasty for physicians and patients, the website www.canaloplasty.com features a number of educational and practice marketing tools, including a comprehensive video library.



The website www.floater-vitreolysis.com provides a wealth of treatment information based on the experience of clinicians worldwide. Topics covered include how to qualify patients for treatment and optimal treatment techniques.


The pressure damage of glaucoma causes a gradual blurring of vision and, if left untreated, can result in total, irreversible blindness. If you suffer from glaucoma, there are several treatment options available. SLT or Selective Laser Trabeculoplasty is a gentle, low-energy laser therapy, which triggers a natural healing response in the eye in order to reduce intraocular pressure. Canaloplasty is an advanced surgical treatment, which works by improving your eye’s natural drainage system.


Vitreous Strands and Opacities (Floaters)

If you suffer from vitreous strands and opacities (commonly referred to as “eye floaters”), then you are already familiar with the frustrating visual disturbance caused by these cobweb and cloud-like shadows. A pain-free, non-invasive laser procedure, vitreolysis can provide much-needed relief from your eye floaters – and help you take back your quality of vision.


Age-Related Macular Degeneration (AMD)

A chronic eye disease, AMD is caused by damage to the eye’s macula and can result in vision loss in the central field of vision, including blurred central vision or a blind spot. Early detection is crucial. Detecting changes early through regular check-ups with your optometrist or ophthalmologist can help to slow the progression of AMD.


Diabetic Eye Disease

High blood sugar levels can damage blood vessels in the retina. This damage is referred to as Diabetic Retinopathy. If untreated over the long-term, Diabetic Retinopathy can cause visual impairment and blindness. In order to preserve vision and prevent progression of Diabetic Retinopathy, it is important to take control of your blood sugar levels, blood pressure, and blood cholesterol.


SLT. The Gentle Alternative for Glaucoma

SLT is a gentle laser therapy, which triggers a natural healing response in the eye to reduce the intraocular pressure associated with glaucoma. It effectively lowers eye pressure in the majority of patients, but the length of time that pressure remains low depends on many factors, including: age and type of glaucoma.

Don’t Let Eye Floaters Cloud Your Vision

Also known as floater laser treatment, vitreolysis is a non-invasive, pain-free procedure that can eliminate the visual disturbance caused by floaters. It is performed in your ophthalmologist’s office and typically takes 20-60 minutes per treatment session.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.

ASX Releases

Ellex Announces Appointment of President, Ellex iTrack™

11 July 2018

Adelaide, Australia, 11 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of Mr. Joaquin Wolff to the position of President, Ellex iTrack™. In this newly created position Mr. Wolff expands the Company’s executive management team and will be dedicated to managing the Ellex iTrack™ business in the rapidly growing minimally invasive glaucoma surgery (MIGS) device market. He will be based out of Ellex iTrack™ headquarters in Fremont in the San Francisco Bay area. Mr. Wolff is a recognized expert in the ophthalmic medical device industry with over 25 years of executive leadership experience. He has held senior management positions in industry- leading companies, including Novartis (Alcon) and Johnson & Johnson (VISX /AMO). In these roles he was responsible for spearheading the launch of several new product platforms in the USA, which attained top market share positions. M


Appointment of Directors

2 July 2018

Adelaide, Australia, 2 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of two new Directors to the Board, Mr. Mike Southard and Mr. Mike Mangano. The appointment will be ratified, by resolution, at the company’s next AGM. Mike Southard Mike Southard spent 25 years with the world’s largest ophthalmology company, Alcon Laboratories of Fort Worth Texas, as Vice President of the Global Surgical business. During Mike’s tenure, the Alcon business grew dramatically from US$85 million to US$2.4 billion of sales per year. Prior to this, he was an executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. Mike is currently actively involved in Ophthalmology, Dermatology and Orthopaedics through his consulting company based in Portland, Oregon, USA. He has vast experience in both the International and U.S. markets an


Ellex iTrack and Ellex Glaucoma Business Third Quarter Sales Update

16 April 2018

 Highlights:  • Sales of Ellex iTrackTM up 57% in the USA and 40% globally compared with the pcp  • Improved new customer acquisition and revenues for Ellex iTrackTM in all but one US territory demonstrates improved geographic penetration  • Global sales of Ellex glaucoma business reached a record US$22.3 million with an acceleration to 40% growth compared with the pcp  Adelaide, Australia 16 April 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced a sales update for Ellex iTrackTM, and its wider glaucoma business, for the 9 months ended 31 March 2018. The wider Ellex glaucoma business comprises the Ellex iTrackTM minimally invasive glaucoma surgery device (MIGS) and the Ellex tangoTM SLT laser for early stage disease. Ellex holds a unique global position for early to mid-stage restorative glaucoma therapy.  Ellex iTrackTM Sales Update  Ellex iTrackTM global sales were US$6.1 million for the


View Share Price

Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.

Corporate Governance

Share Trading Policy